M2-like macrophages exert hepatoprotection in acute-on-chronic liver failure through inhibiting necroptosis-S100A9-necroinflammation axis

Abstract Necroptosis has emerged as a novel and crucial player in acute and chronic liver diseases. Necroptotic cells lead to the release of DAMPs including S100A9, followed by the development of necroinflammation. We previously have documented the beneficial hepatoprotection conferred by M2-like ma...

Full description

Bibliographic Details
Main Authors: Li Bai, Ming Kong, Zhongping Duan, Shuang Liu, Sujun Zheng, Yu Chen
Format: Article
Language:English
Published: Nature Publishing Group 2021-01-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-020-03378-w
_version_ 1818393416439955456
author Li Bai
Ming Kong
Zhongping Duan
Shuang Liu
Sujun Zheng
Yu Chen
author_facet Li Bai
Ming Kong
Zhongping Duan
Shuang Liu
Sujun Zheng
Yu Chen
author_sort Li Bai
collection DOAJ
description Abstract Necroptosis has emerged as a novel and crucial player in acute and chronic liver diseases. Necroptotic cells lead to the release of DAMPs including S100A9, followed by the development of necroinflammation. We previously have documented the beneficial hepatoprotection conferred by M2-like macrophages in acute-on-chronic liver failure (ACLF) in vitro and in vivo, namely, M2-like macrophages protect hepatocytes against apoptosis. Herein, we integrated necroptosis, S100A9, and necroinflammation into this hepatoprotection, and hypothesized M2-like macrophages exert a hepatoprotective effect through inhibiting necroptosis-S100A9-necroinflammation axis. To testify this hypothesis, control mice were pre-treated with necroptosis or S100A9 inhibitors followed by D-GalN/LPS challenge. The extent of liver injury and M1/M2 macrophage activation was assessed. Necroptosis signaling and S100A9 expression were analysed and compared in control and fibrotic mice with or without acute insult. To document the pivotal role of M2-like macrophages in necroptosis and S100A9 inhibition, loss-of-function and gain-of-function experiments were performed. In addition, necroinflammation and its dependence on necroptosis and S100A9 were analysed. Moreover, the inhibitory effects of M2-like macrophages on necroinflammation were investigated in vivo and in vitro. We found that: firstly, the inhibition of necroptosis signaling and S100A9 expression alleviated D-GalN/LPS-induced hepatic damage, which was accompanied by M2-like macrophage activation; secondly, fibrosis inhibited necroptosis signaling and S100A9 expression, which could be attributed to M2-like macrophage activation; thirdly, S100A9 may function as a downstream player of necroptosis signaling; fourthly, fibrosis suppressed necroptosis- and S100A9-dependent necroinflammation; and finally, M2-like macrophages inhibited NLRP3 inflammasome activation and resultant necroinflammation via IL-10. Therefore, M2-like macrophages exert a beneficial hepatoprotection by inhibiting necroptosis-S100A9-necroinflammation axis in ACLF. Our findings provide novel insight for treating ACLF patients by specially targeting this signaling axis.
first_indexed 2024-12-14T05:44:58Z
format Article
id doaj.art-8a70770b526c4973a2b38c8fa15ea34c
institution Directory Open Access Journal
issn 2041-4889
language English
last_indexed 2024-12-14T05:44:58Z
publishDate 2021-01-01
publisher Nature Publishing Group
record_format Article
series Cell Death and Disease
spelling doaj.art-8a70770b526c4973a2b38c8fa15ea34c2022-12-21T23:14:54ZengNature Publishing GroupCell Death and Disease2041-48892021-01-0112111310.1038/s41419-020-03378-wM2-like macrophages exert hepatoprotection in acute-on-chronic liver failure through inhibiting necroptosis-S100A9-necroinflammation axisLi Bai0Ming Kong1Zhongping Duan2Shuang Liu3Sujun Zheng4Yu Chen5Beijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, the Fourth Department of hepatology, Beijing YouAn Hospital, Capital Medical UniversityBeijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, the Fourth Department of hepatology, Beijing YouAn Hospital, Capital Medical UniversityBeijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, the Fourth Department of hepatology, Beijing YouAn Hospital, Capital Medical UniversityBeijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, the Fourth Department of hepatology, Beijing YouAn Hospital, Capital Medical UniversityBeijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, the Fourth Department of hepatology, Beijing YouAn Hospital, Capital Medical UniversityBeijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, the Fourth Department of hepatology, Beijing YouAn Hospital, Capital Medical UniversityAbstract Necroptosis has emerged as a novel and crucial player in acute and chronic liver diseases. Necroptotic cells lead to the release of DAMPs including S100A9, followed by the development of necroinflammation. We previously have documented the beneficial hepatoprotection conferred by M2-like macrophages in acute-on-chronic liver failure (ACLF) in vitro and in vivo, namely, M2-like macrophages protect hepatocytes against apoptosis. Herein, we integrated necroptosis, S100A9, and necroinflammation into this hepatoprotection, and hypothesized M2-like macrophages exert a hepatoprotective effect through inhibiting necroptosis-S100A9-necroinflammation axis. To testify this hypothesis, control mice were pre-treated with necroptosis or S100A9 inhibitors followed by D-GalN/LPS challenge. The extent of liver injury and M1/M2 macrophage activation was assessed. Necroptosis signaling and S100A9 expression were analysed and compared in control and fibrotic mice with or without acute insult. To document the pivotal role of M2-like macrophages in necroptosis and S100A9 inhibition, loss-of-function and gain-of-function experiments were performed. In addition, necroinflammation and its dependence on necroptosis and S100A9 were analysed. Moreover, the inhibitory effects of M2-like macrophages on necroinflammation were investigated in vivo and in vitro. We found that: firstly, the inhibition of necroptosis signaling and S100A9 expression alleviated D-GalN/LPS-induced hepatic damage, which was accompanied by M2-like macrophage activation; secondly, fibrosis inhibited necroptosis signaling and S100A9 expression, which could be attributed to M2-like macrophage activation; thirdly, S100A9 may function as a downstream player of necroptosis signaling; fourthly, fibrosis suppressed necroptosis- and S100A9-dependent necroinflammation; and finally, M2-like macrophages inhibited NLRP3 inflammasome activation and resultant necroinflammation via IL-10. Therefore, M2-like macrophages exert a beneficial hepatoprotection by inhibiting necroptosis-S100A9-necroinflammation axis in ACLF. Our findings provide novel insight for treating ACLF patients by specially targeting this signaling axis.https://doi.org/10.1038/s41419-020-03378-w
spellingShingle Li Bai
Ming Kong
Zhongping Duan
Shuang Liu
Sujun Zheng
Yu Chen
M2-like macrophages exert hepatoprotection in acute-on-chronic liver failure through inhibiting necroptosis-S100A9-necroinflammation axis
Cell Death and Disease
title M2-like macrophages exert hepatoprotection in acute-on-chronic liver failure through inhibiting necroptosis-S100A9-necroinflammation axis
title_full M2-like macrophages exert hepatoprotection in acute-on-chronic liver failure through inhibiting necroptosis-S100A9-necroinflammation axis
title_fullStr M2-like macrophages exert hepatoprotection in acute-on-chronic liver failure through inhibiting necroptosis-S100A9-necroinflammation axis
title_full_unstemmed M2-like macrophages exert hepatoprotection in acute-on-chronic liver failure through inhibiting necroptosis-S100A9-necroinflammation axis
title_short M2-like macrophages exert hepatoprotection in acute-on-chronic liver failure through inhibiting necroptosis-S100A9-necroinflammation axis
title_sort m2 like macrophages exert hepatoprotection in acute on chronic liver failure through inhibiting necroptosis s100a9 necroinflammation axis
url https://doi.org/10.1038/s41419-020-03378-w
work_keys_str_mv AT libai m2likemacrophagesexerthepatoprotectioninacuteonchronicliverfailurethroughinhibitingnecroptosiss100a9necroinflammationaxis
AT mingkong m2likemacrophagesexerthepatoprotectioninacuteonchronicliverfailurethroughinhibitingnecroptosiss100a9necroinflammationaxis
AT zhongpingduan m2likemacrophagesexerthepatoprotectioninacuteonchronicliverfailurethroughinhibitingnecroptosiss100a9necroinflammationaxis
AT shuangliu m2likemacrophagesexerthepatoprotectioninacuteonchronicliverfailurethroughinhibitingnecroptosiss100a9necroinflammationaxis
AT sujunzheng m2likemacrophagesexerthepatoprotectioninacuteonchronicliverfailurethroughinhibitingnecroptosiss100a9necroinflammationaxis
AT yuchen m2likemacrophagesexerthepatoprotectioninacuteonchronicliverfailurethroughinhibitingnecroptosiss100a9necroinflammationaxis